跳至主要内容
临床试验/NCT04247035
NCT04247035Unknown不适用

Non-Interventional, Multi-center Registry of Recording of Treatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer

Hellenic Society of Medical Oncology1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2019年1月31日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
300
试验地点
1
主要终点
Evaluation of the outcome per treatment line

研究概览

简要总结

• To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece

详细描述

  • To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece
  • To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival
  • To record adverse events per line of therapy
  • To recording of the causes of treatment discontinuation per line of therapy

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Women with histological confirmed ER/PR positive, HER2-negative MBC
  • Age >18 years old
  • Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC
  • Adequate hematologic, renal and hepatic function
  • Signed informed consent (ICF)

排除标准

  • Active malignancy other than MBC
  • Active infection

结局指标

主要结局

Evaluation of the outcome per treatment line

时间窗: 5 years

To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival

次要结局

未报告次要终点

研究者

发起方
Hellenic Society of Medical Oncology
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验